Search results for "ADC"

FDA Approves Clinical Trial for Abl Bio’s Dual-Antibody ADC Candidate

FDA Approves Clinical Trial for Abl Bio’s Dual-Antibody ADC Candidate

Abl Bio announced on March 3rd that the U.S. Food and Drug Administration has approved the Investigational New Drug application for its dual-antibody...
A Ray of Hope: ‘Low Expression’ Changes the Landscape of Breast Cancer Treatment

A Ray of Hope: ‘Low Expression’ Changes the Landscape of Breast Cancer Treatment

The treatment landscape for metastatic breast cancer is undergoing a significant shift. On February 20, Daiichi Sankyo Korea and AstraZeneca Korea...
Can We Break Through Chemotherapy Resistance? A New Target for Triple-Negative Breast Cancer Appears

Can We Break Through Chemotherapy Resistance? A New Target for Triple-Negative Breast Cancer Appears

Among breast cancers, ‘triple-negative breast cancer ’ is particularly challenging to treat.
Ligakem Bio Receives ADC Platform Technology Fees from Ono Pharmaceutical

Ligakem Bio Receives ADC Platform Technology Fees from Ono Pharmaceutical

Ligakem Bioscience announced on the 8th that it is set to receive milestone payments related to the development...
K-Bio Targets Global Expansion: HK inno.N and HLB Seek FDA Approval

K-Bio Targets Global Expansion: HK inno.N and HLB Seek FDA Approval

South Korean pharmaceutical and biotech companies are aggressively pursuing product approvals and clinical trials with...
LigaChemBio Receives Milestone from Czech Sotio Biotech

LigaChemBio Receives Milestone from Czech Sotio Biotech

LigaChem Biosciences announced on the 9th that it will receive milestone payments based on successful product...
Dr. Han Jin-hwan, Formerly of Merck (MSD), Appointed Head of New Drug Research Institute at Ligand Pharmaceuticals

Dr. Han Jin-hwan, Formerly of Merck (MSD), Appointed Head of New Drug Research Institute at Ligand Pharmaceuticals

Ligand Pharmaceuticals announced on the 5th that it has recruited Dr. Han Jin-hwan, formerly of Merck, as the head of...